Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
- DOI
- 10.1016/s2213-8587(26)00125-7
- Published
- 2026 Aug
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-26-00125-7,
title = {Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.},
author = {Buse JB and Bajaj HS and Dalskov SM and Donaldson L and Hansen Duus HH and Fabricius TW and Haluzík M and Lingvay I and Pedersen SD and Pratley RE and Jain AB and REIMAGINE 2 study group},
year = {2026},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(26)00125-7},
url = {https://doi.org/10.1016/s2213-8587(26)00125-7}
}RIS
TY - JOUR TI - Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. AU - Buse JB AU - Bajaj HS AU - Dalskov SM AU - Donaldson L AU - Hansen Duus HH AU - Fabricius TW AU - Haluzík M AU - Lingvay I AU - Pedersen SD AU - Pratley RE AU - Jain AB AU - REIMAGINE 2 study group PY - 2026 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(26)00125-7 UR - https://doi.org/10.1016/s2213-8587(26)00125-7 ER -
APA
JB, B., HS, B., SM, D., L, D., HH, H. D., TW, F., M, H., I, L., SD, P., RE, P., AB, J., & group, R. 2. S. (2026). Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(26)00125-7
Source records
- pubmed · retrieved 2026-09-26T17:17:44.120Z
- europe-pmc · retrieved 2026-09-26T17:17:44.134Z